These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27955980)

  • 1. The metabolism of glucocerebrosides - From 1965 to the present.
    Futerman AH; Platt FM
    Mol Genet Metab; 2017; 120(1-2):22-26. PubMed ID: 27955980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
    Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
    PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
    Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
    J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.
    Pandey MK; Burrow TA; Rani R; Martin LJ; Witte D; Setchell KD; Mckay MA; Magnusen AF; Zhang W; Liou B; Köhl J; Grabowski GA
    Nature; 2017 Mar; 543(7643):108-112. PubMed ID: 28225753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable In Vivo Preclinical Studies of Neuronopathic Gaucher Disease.
    Hamler R; Brignol N; Clark SW; Morrison S; Dungan LB; Chang HH; Khanna R; Frascella M; Valenzano KJ; Benjamin ER; Boyd RE
    Anal Chem; 2017 Aug; 89(16):8288-8295. PubMed ID: 28686011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
    Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.
    Bodennec J; Pelled D; Riebeling C; Trajkovic S; Futerman AH
    FASEB J; 2002 Nov; 16(13):1814-6. PubMed ID: 12223447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic delivery of recombinant glucocerebrosidase enzyme-containing extracellular vesicles to human cells from Gaucher disease patients.
    Janpipatkul K; Sutjarit N; Tangprasittipap A; Chaiamarit T; Innachai P; Suksen K; Chokpanuwat T; Tim-Aroon T; Anurathapan U; Jearawiriyapaisarn N; Tubsuwan A; Bowornpinyo S; Asavapanumas N; Chairoungdua A; Bhukhai K; Hongeng S
    Orphanet J Rare Dis; 2024 Oct; 19(1):363. PubMed ID: 39358794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuronal forms of Gaucher disease.
    Vitner EB; Futerman AH
    Handb Exp Pharmacol; 2013; (216):405-19. PubMed ID: 23563668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gaucher disease: Progress and ongoing challenges.
    Mistry PK; Lopez G; Schiffmann R; Barton NW; Weinreb NJ; Sidransky E
    Mol Genet Metab; 2017; 120(1-2):8-21. PubMed ID: 27916601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy.
    Kacher Y; Brumshtein B; Boldin-Adamsky S; Toker L; Shainskaya A; Silman I; Sussman JL; Futerman AH
    Biol Chem; 2008 Nov; 389(11):1361-9. PubMed ID: 18783340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro accumulation of glucocerebroside in neuroblastoma cells: a model for study of Gaucher disease pathobiology.
    Prence EM; Chaturvedi P; Newburg DS
    J Neurosci Res; 1996 Feb; 43(3):365-71. PubMed ID: 8714525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.
    Ivanova MM; Dao J; Kasaci N; Adewale B; Nazari S; Noll L; Fikry J; Sanati AH; Goker-Alpan O
    PLoS One; 2021; 16(10):e0247211. PubMed ID: 34695170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipids regulate the hydrolysis of membrane bound glucosylceramide by lysosomal β-glucocerebrosidase.
    Abdul-Hammed M; Breiden B; Schwarzmann G; Sandhoff K
    J Lipid Res; 2017 Mar; 58(3):563-577. PubMed ID: 28126847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapeutic targets for Gaucher disease.
    Vitner EB; Vardi A; Cox TM; Futerman AH
    Expert Opin Ther Targets; 2015 Mar; 19(3):321-34. PubMed ID: 25416676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
    Atrian S; López-Viñas E; Gómez-Puertas P; Chabás A; Vilageliu L; Grinberg D
    Proteins; 2008 Feb; 70(3):882-91. PubMed ID: 17803231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction with ERp57 is required for progranulin protection against Type 2 Gaucher disease.
    Liu Y; Zhao X; Jian J; Hasan S; Liu C
    Biosci Trends; 2023 May; 17(2):126-135. PubMed ID: 36889696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients-A Qualitative and Quantitative Approach.
    Szymańska-Rożek P; Czartoryska B; Kleinotiene G; Lipiński P; Tylki-Szymańska A; Ługowska A
    Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.
    Sun Y; Liou B; Xu YH; Quinn B; Zhang W; Hamler R; Setchell KD; Grabowski GA
    J Biol Chem; 2012 Feb; 287(6):4275-87. PubMed ID: 22167193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.